Radius Health News and Activities

Radius Health is owned by Gurnet Point Capital.

They are in:

• Pharmaceuticals67%
• Fund33%

View the org chart displaying its 14 main executives

Most searched biographies at Radius Health

• Scott Briggs, President & Chief Executive Officer
• Joan Gray, Head of Human Resources
• Erika Tooman, Chief Legal Officer

Popular executive movements at Radius Health

• Bethany Sensenig, Chief Financial Officer, has left the company  (posted on April 16 2026).
• Ciara Murphy, Corporate Controller, has left the company  (posted on April 16 2026).
• Kimberly Labagnara, Director of Marketing, Patient and Consumer, has left the company  (posted on April 16 2026).

Click here to view some more movements at Radius Health

Create your alert
to follow the executive moves at Radius Health.

Gurnet Point Capital has 1,920 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Catalyst Pharmaceuticals, listed under ticker CPRX, has been delisted. (posted on July 13 2026).
• Angelini Pharma has acquired Catalyst Pharmaceuticals (posted on July 13 2026).
• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Richard Saynor - Chief Executive Officer at Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson

Learn more about the Pharmaceuticals industry

Press releases by Radius Health

• Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium | Radius
• Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome | Radius
• Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital | Radius
• Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant | Radius
• Radius Health Expands Non-US Market Footprint for TYMLOS | Radius
• Radius Files Definitive Proxy and Mails Letter to Stockholders | Radius
• Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | Radius
• Radius Health Update on Abaloparatide Transdermal System | Radius
• Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors | Radius
• Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology | Radius
• View more press releases Close

Social media about Radius Health

• Radius Health on Wikipedia, Google News & Yahoo Finance
• Radius Health on LinkedIn, X (Twitter) & YouTube